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Chronic pain indicates a type of pain that lasts over time and is accompanied by diagnostic
and therapeutic difﬁculties. It follows that treatment failures are common and patients
roam from doctor to doctor in search of an effective care program. So there is an urgent
need for long-acting and effective therapeutics to alleviate symptoms of the varied forms
of chronic pain. During the past few years, a good success has been achieved with a de-
rivative of a neurotoxin. It has been shown that administration of this toxin can block the
release of neurotransmitters and pain mediators. Botulinum neurotoxin type A (BoNT/A) is
well known as a treatment for neuromuscular conditions such as dystonia and spasticity.
However, the clinical application for BoNT/A has continued to expand. Its analgesic effect
has been used in clinical practice with satisfactory results. This review provides an
introduction of a hypothesis for the mechanism by which BoNT/A eases chronic pain. It
also summarizes the clinical therapeutic effects of BoNT/A in different types of chronic
pain and its potential prospects.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license. 1. Introduction
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Fig. 1. Botulinum neurotoxins consist of three domains. The NH2-terminal
domain (L-chain domain) is a zinc endopeptidase that represents the cata-
lytic domain expressing the protease activity (Montal, 2010). The other two
domains (H-chain domain) are the central domain, whose function is related
to the membrane translocation of L-chain into the neuronal cytosol and the
COOH-terminal domain (HC); which consists of two equally size sub-
domains and is for the neurospeciﬁc binding.
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of the neuronal exocytosis of transmitters and pain media-
tors that exhibit unique antinociceptive activity. Based on
the results of the progressively increasing studies, Botuli-
num neurotoxin type A (BoNT/A) met the requirements
perfectly. In this review, we have provided a hypothesis for
themechanismof action of BoNT/A and explain how it eases
chronic pain using the latest evidence from animal models.
Furthermore, we have summarized the clinical therapeutics
of BoNT/A in different types of chronic pain. Finally, we have
presented the reason behind its potential in protein
engineering.
2. Development of BoNTs and their analgesic effect
Botulinum neurotoxins (BoNTs), the most poisonous
biological substances known, are produced by anaerobic
bacteria of the genus Clostridium (Simpson, 1981; Gill,
1982). However, it was not until nearly 30 years later that
the ﬁrst batch of crystalline toxinwas produced. Apart from
the well-known therapeutic use in muscular hyperactivity
and certain autonomic disorders (Mahant et al., 2000),
BoNTs were also used in the treatment of pain. The bene-
ﬁcial effects of BoNTs include the remission of migraine,
neuropathic pain, joint pain and back pain. In 2010, Qerama
et al. reported the hypothesis that BoNTs inhibit the local
neurotransmitter that is released from sensory nerve end-
ings by peripheral SNAP-25 (Synaptosomal associated
protein of 25 kDa) cleavage; which is similar to the activity
in cholinergic neurons (Qerama et al., 2010; Cui et al.,
2004). The recent studies of mirror pain and poly-
neuropathy models (paclitaxel-induced polyneuropathy,
diabetic neuropathy) (Favre-Guilmard et al., 2009; Bach-
Rojecky et al., 2010) cannot be explained only by local ac-
tion on the sensory nerve endings adjacent to the site of
injection because of the unilateral BoNTs and their bilateral
effects. Furthermore, the destination of the transported
BoNTs has remained unknown and the functional signiﬁ-
cance of BoNTs axonal transport from periphery to the CNS
(Bach-Rojecky et al., 2010) needs to be explained. In the
end, these are some of the issues that need to be urgently
resolved.
3. The connections between the structure of BoNT/A
and its unique function
BoNTs are a group of homologous di-chain proteins
(serotypes A-G) with distinct characteristics (Fig. 1). It
originates from Clostridium botulinum whose active form
consists of a Zn2þ-dependent proteolytic light chain (LC,
50 kDa) linked to a heavy chain (HC, 100 kDa) via a disul-
phide and non-covalent bonds (Dolly and O’Connell, 2012).
When BoNTs are injected into a target tissue, its heavy
chain binds to glycoprotein structures speciﬁcally found on
cholinergic nerve terminals; which can explain its high
selectivity for cholinergic synapses. After internalization,
the light chain binds to the SNARE protein complex with a
high speciﬁcity. The target proteins vary amongst the BoNT
serotypes (Dressler et al., 2005). What we have focused on
in this study is the BoNT/A that cleaves the synaptosomal-
associated proteins of 25 kDa (SNAP-25). In 2010, Montal Mprovided an outline of BoNT protein design and function.
The HC, HN and LC regions are responsible for binding,
translocation and protease activity; respectively (Montal,
2010). In this study, we have tried to combine the infor-
mation provided to us through literature with the evidence
we have found in the animal models in order to reasonably
explain the molecular mechanism of BoNT action. Never
the less, further details need to be gathered by more
extensive studies.
3.1. The analgesic effect of BoNT in the animal model of
inﬂammatory pain
3.1.1. Formalin model
The formalin model is a preclinical model used to
investigate the analgesic effect of some drugs. It always
elicits pain-related behavior, such as licking, biting and
shaking. Injection of formalin into the plantar surface of
the hind paw produced a biphasic response of neuronal
excitation (Lee et al., 2011). Cui et al. (Aoki, 2005) showed
that subcutaneous injection of BoNT/A into the rat paw
signiﬁcantly reduced formalin pain during phase two,
inhibited the glutamate release in the hind paw, reduced
the number of formalin-induced Fos-like immunoreactive
cells in the dorsal horn of the spinal cord and signiﬁcantly
inhibited the excitation of wide dynamic range neurons of
the dorsal horn in phase two. All of these ﬁndings
demonstrated that the BoNT/A does not exert a local
analgesic effect but reduces central sensitization (Aoki and
Francis, 2011).
3.1.2. Capsaicin model (TRPV1, SP and CGRP)
The capsaicin model of inﬂammatory pain is to excite
the sensory neurons with capsaicin; which is an irritant
derivative from chilli peppers. It binds to the cation channel
of the transient receptor potential vanilloid type 1 (TRPV1);
which is located on C-ﬁbers (Lomas et al., 2008). This model
can cause intense pain due to the release of neuropeptides
such as substance P and CGRP (Bach-Rojecky and Lackovic,
2005). Bach-Rojecky et al. reported that pre-treatment
with BoNT/A for six days before induction signiﬁcantly
Fig. 2. When we inject botulinum neurotoxin type A into the peripheral
nociceptive neurons, its analgesic effect can be direct, peripherally and in-
direct, centrally because of the retrograde transport (Dolly and O’Connell,
2012). When intrathecally injected, botulinum neurotoxin type A may
inhibit the release of neurotransmitters from central terminals (Dolly and
O’Connell, 2012). The analgesic effect may occur in both peripheral and
central level at the same time. Symbols: SP: Substance P; CGRP: Calcitonin
gene-related peptide; TRPV1: Transient receptor potential vanilloid 1; Fos;
Glutamate.
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and Lackovic, 2005).
3.2. The analgesic effect of BoNT in the animal model of
neuropathic pain
3.2.1. The chronic constriction injury model
The chronic constriction injury (CCI) of sciatic nerve was
used as a model of neuropathic pain. This model was
originally proposed by Bennett and Xie (1988) and can be
adapted for both rats and mice. The study conducted by
Marinelli et al., in 2010 (Marinelli et al., 2010) mainly
investigated the effects of BoNT/A on neuropathic pain.
They demonstrated that the BoNT/A counteracted the
neuropathic pain induced by chronic constriction injury
(CCI) to the sciatic nerve both in mice and in rats. They
suggest that this effect was already present after a single
intraplantar (i.pl.) or intrathecal (i.t.) neurotoxin adminis-
tration. This signiﬁcantly reduced the sciatic nerve ligation-
induced mechanical allodynia in mice and rats along with
the thermal hyperalgesia in rats. This effect on the CCI
model indicated the BoNT/A interfering function mediated
by blocking neuroexoctosis through the cleavage of
synaptosome-associated protein of SNAP-25. Meanwhile,
according to the previous reports, the inhibitory effects on
GABA (Verderio et al., 2004), glutamate (Cui et al., 2004),
CGRP (Lucioni et al., 2008) and SP (Ishikawa et al., 2000) are
also involved in CCI model. Therefore, the mechanism
should be similar to that of the inﬂammation pain.
Furthermore, Marinelli et al. reported that a single injection
of BoNT/A was sufﬁcient not only to reduce the mechanical
allodynia and cold hyperalgesia but also to improve the
functional recovery of injured paw and to enhance the
regeneration processes in the injured nerve (Marinelli et al.,
2010). It is extremely important that BoNT/A exerts anal-
gesic effects and simultaneously is able to accelerate the
process of nerve regeneration (Marinelli et al., 2010), which
opens promising prospects on the development of new
pharmacotherapeutic approach against neuropathic pain.
3.2.2. Model of diabetic neuropathic pain
The model of diabetic neuropathic pain is another
frequently-used neuropathic pain. Rats were induced to
become diabetic by a single intraperitoneal injection of
streptozotocin (80 mg/kg). In 2010, Bach-Rojecky et al.
(Bach-Rojecky et al., 2010) reported that the diabetic ani-
mals with at least 25% lower pain thresholds compared to
that of the non-diabetic group were considered neuro-
pathic and were injected with BoNT/A either subcutane-
ously (3, 5 and 7 U/kg) or intrathecally (1 U/kg). The results
presented as pain reduction after BoNT/A injection in the
animals with diabetic neuropathy. They also shared their
hypothesis on the mechanism of this effect based on their
results. Basically, they believed that the bilateral pain
reduction after unilateral toxin application and the effec-
tiveness of lower dose with the faster onset after the
intrathecal injection was suggestive of the involvement of
the central nervous system in the antinociceptive action of
BoNT/A in painful diabetic neuropathy. This is in agreement
with the results in the inﬂammation model (Aoki and
Francis, 2011).3.3. A summarized proposed mechanism based on the animal
model
Summing up all the results reviewed earlier and refer-
ring to the mechanism of action discussed in the literature
(Dolly and O’Connell, 2012) (Ishikawa et al., 2000), we
suggest a potential mechanism of action for BoNT/A anal-
gesic effect on pain transmission (Fig. 2). The administra-
tion of BoNT/A in peripheral nociceptive neurons plays a
direct role in its peripheral analgesic effect and an indirect
role in its central analgesic effect because of retrograde
transport. It can also have analgesic effects by inhibiting the
release of the neurotransmitter with its administration in
the central nociceptive neurons.4. BoNT-based neurotherapeutics in the patients with
chronic pain
The international association for the study of pain has
deﬁned the chronic pain as what persists after the injury
when healing has ceased. Chronic pain is involved in some
major health problems in a range of conditions including:
diabetic polyneuropathy, chronic back and shoulder pains,
myofacial pain, arthritis pain and multiple sclerosis pain.
This kind of pain has disturbed the life balance of many
people and imposed an enormous impact on both the
economy and the quality of life of many sufferers. Unfor-
tunately, the majority of the sufferers do not use the
currently available non-addictive medicines. What is worse
is that the commonly used analgesics are short-acting and
cause unwanted adverse effects; which raises serious
problems upon repeated use over long period (Dolly and
O’Connell, 2012).
It has been proven that BoNT/A causes selective weak-
ness in the painful muscles and disrupts the spasm–pain
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patients to perform physical exercises that are fundamental
for long-term recovery (Ishikawa et al., 2000). Furthermore,
enormous number of studies showed that BoNT/A offered a
new direction to ease the chronic pain.
4.1. Migraine
Migraine is a chronic neurovascular disorder that ac-
counts for suffering of 2%–15% of the world’s population.
Migraine is characterized by severe headaches and is often
accompanied with nausea, vomiting and increased sensi-
tivity to sound and light. Some sufferers cannot receive an
effective therapy from the doctors and as a result, they
don’t even consult a physician in future occasions. The
commonly used prophylaxis agents for migraine include b-
adrenergic blockers, calcium channel blockers (CCBs), tri-
cyclic antidepressants (TCAs) and anticonvulsants. Due to
the adverse effect proﬁle and limited efﬁcacy of the
currently available therapies, the potent neurotoxin, BoNT/
A has been introduced to intensive clinical investigation for
the treatment of migraine and other types of headache
(Colhado et al., 2009). A double-blind, randomized
placebo-controlled study of 30 migraine sufferers revealed
that BoNT/A treatment was well tolerated and the fre-
quency of the attacks were signiﬁcantly reduced at day 90.
Likewise, the frequency of the severe bouts was signiﬁ-
cantly reduced at days 60 and 90 (Barrientos and Chana,
2003).
Another double-blind, placebo-controlled trial was
performed to investigate if this bio therapeutic would be
suitable to treat chronic tension-type headache. All suffers
responded positively to local injections of BoNT/A that
resulted in less headaches and precranial muscle tender-
ness (Dolly and O’Connell, 2012) (Relja and Telarovic,
2004). Furthermore, Elza compared BoNT/A with other
currently available drugs for the treatment of migraines.
Their results suggested that the BoNT/A was more effective
for the group of patients with frequent episodic migraines.
However, considering the clinical beneﬁts and the lack of
undesirable side effects such as weight gain and con-
stipation, they argued that BoNT/A should be considered
for use in the patients with chronic headaches as an alter-
native therapy or in patients with contraindications for the
use of other classes of drugs. They also reminded that
further investigation is needed to deﬁne patient subgroups
that might beneﬁt from BoNT/A (Magalhães et al., 2010).
4.2. Arthritis joint pain
Arthritis is an important and growing public health
problem (Lawrence et al., 2008), There is a growing need
for novel treatments of refractory arthritis joint pain as
aging population is expanding with many sufferers who
cannot receive the joint replacement surgery. In 2008,
Jasvinder et al. reported the use of intra-articular BoNT/A in
two rheumatoid arthritis (RA) patients with persistent
painful monoarthritis in ankle/feet joints. Both patients had
monaticular pain despite a good response of all other joints
to a combination therapy that also included anti-tumor
necrosis factor therapy. All intra-articular corticosteroidinjections and declined surgical options were failed in both
patients. They beganwith a single “off-label” intra-articular
injection of BoNT/A into the right ankle (100 units) and left
ﬁrst metatarsophalangeal joint (25 units). As a result, their
pain and function improved signiﬁcantly (>40%) in both
patients and the function lasted 15–18 months. They
concluded that the intra-articular BoNT/A may provide an
additional therapeutic option in RA patients with persistent
monoarthritis (Singh and Mahowald, 2009). In 2009,
Maren et al. conducted several small open label studies in
which they injected BoNT/A into the joints with arthritis.
They found that two third of the patients had more than
50% reduction in the joint pain severity that was associated
with a signiﬁcant improvement in function. Importantly, no
serious adverse effects of BoNT/A were reported. They
continued their studies using the same method in shoul-
ders and knees. The results showed that BoNT/A produced a
signiﬁcant decrease in shoulder pain severity in one month
(6.8–4.4 on VAS, p ¼ 0.22). Furthermore, BoNT/A produced
a signiﬁcant 48% decrease in McGill Total Pain Score in the
knees in one month (p ¼ 0.11). This was still signiﬁcant
three months after the injection (p ¼ 0.02). This group
pointed out that more studies need to be conducted for the
dose range and the interval of the BoNT/A injections (Chou
et al., 2010).
4.3. Myofascial pain syndrome
Myofascal pain syndrome (MFPS) is characterized by the
presence of trigger points, palpable muscle abnormality
and referred pain distal to the trigger point. Most of its
treatments are aimed to reduce the pain in trigger points
and to reduce themuscle spasm. The traditional treatments
of MFPS consist of physical therapy, oral medications and
trigger point injections (Annaswamy et al., 2011). In 2010,
Delaram et al. reported two cases where proximal myo-
fascial pain in complex regional pain syndrome (CPRS) was
treated with an injection of 20 units of BoNT/A in each
trigger point. The therapeutic effect was reported to be
satisfactory. However, there are limited number of reports
on myofascial pain syndrome in the literature. Therefore,
this area needs more continued research and exploration
(Safarpour and Jabbari, 2010).
4.3.1. Trigeminal neuralgia
Trigeminal neuralgia (TN) is a severe chronic pain syn-
drome characterized by an excruciating, brief electric
shocklike paroxysmal pain in one or more divisions of the
trigeminal nerve. It can occur either spontaneously or upon
gentle tactile stimulation of a trigger zone on the face or in
the oral cavity (Fields, 1996; Cheshire, 2007; Devor et al.,
2002). There are two major methods of treatment for TN;
pharmacotherapy and neurosurgical procedures. Pharma-
cotherapy is the routine way of treatment and includes the
use of antiepileptic drugs like carbamazepine with the
secondary drug choice to be baclofen, lamotrigine, oxca-
bazepine, phenytoin, gabapentin or sodium valproate
(Merrison and Fuller, 2003). This is generally safer and
more suitable for medically compromised patients who
cannot undergo surgery. For those patients who do not
respond well to medical management, surgery is the only
Fig. 3. This creative composite toxin has advantageous components of two
botulinum neurotoxins. To achieve this, light chain protease of botulinum
neurotoxin type E (LC/E); which is the most effective and robust inhibitor of
neuro-exocytosis, is attached to the light chain of botulinum neurotoxin type
A (LC/A (H227Y)), with HN/A, the translocation, and COOH-terminal domain
(HC/A) to form a channel for delivering proteases and binding acceptors on
neurons (Wang et al., 2011). This new method successfully created a new
active bio-therapeutic protein LC/E-BoTIM/A.
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cessful use of BoNT/A in patients with TN seem to give us a
new way to subside this kind of refractory chronic pain. In
2005, Piovesan et al. reported their success in nearly
complete pain relief in all of their 13 patients with sub-
dermal injections of BoNT/A at a mean dose of 3.22 units/
cm2 directly into the affected facial regions for 10 days. The
patients were followed up for 60 days (Piovesan et al.,
2005). Allam et al. reported a longer duration of pain re-
lief for 90 days in their single patient (Allam et al., 2005). In
2009, Wei et al. achieved a longer pain-free duration of ﬁve
months. However, the doses used in the study were several
times higher (100 units) than that of the former studies.
The injection was performed subcutaneously into the right
external nasal trigger zone (60 units) and to the right
mental nerve region (40 units). The pain recurred ﬁve
months later and the site was again injected with 100 units
of BoNT/A. In their study, the repeated injections were
useful in promoting a continuous pain-free state. However,
the patient lost the nasolabial fold on the right side of the
face (Ngeow and Nair, 2010). Therefore, the doses need
further conﬁrmation with more studies.
4.3.2. Other types of chronic pain
Beside the therapeutic effects reviewed above, there are
some other kinds of chronic pain that can be treated. In
2010, Santamato et al. reported the treatment of the neck
pain that was related to nocturnal bruxismwith BoNT/A. In
this study, each masseter muscle was injected with a dose
of about 40 units and the temporal muscle was bilaterally
injected with 25 units. After three days of treatment with
BoNT/A, a decrease in bruxism symptoms was noted
(Santamato et al., 2010). Furthermore, Jason Abbott also
used BoNT/A in women with chronic pelvic pain in 2009.
They indicated that BoNT/A (20–40 units) used in the vulva
may have a continued beneﬁt for 3–6 months after injec-
tion with limited side effects (Abbott, 2009).
5. The bright future for the BoNT-based
neurotherapeutics
The LC in the type E BoNT gives rise to a more exten-
sively truncated SNAP-25 product that is unable to form
functional complexes with its SNARE partners. Therefore, it
offers a more fast acting effect compared to that of BoNT/A.
Besides, it can also pseudo-irreversibly abolish release of
neurotransmitters. Generally speaking, BoNT/E blocks the
neurotransmission more quickly and more potently
compared to BoNT/A. However, the clinical application of
BoNT/A is restricted by its neuromuscular paralytic action
being transient (less than 4 weeks) in contrast to BoNT/A
(more than 4 months). In the past few years, Meng J re-
ported the construction of a chimera of BoNT/A and/E by
introducing a nucleotide sequence encoding the acceptor
binding Hc domain of type A into the BoNT/E gene (Fig. 3).
The recombinant EA chimeric protein can then be
expressed in Escherichia coli and be puriﬁed. They found
that it cleaved SNAP-25 in the trigeminal neurons and
blocked CGRP release triggered by all stimuli tested,
including capsaicin (Wang et al., 2011). After that, some
people proved that it was possible to show this dramaticincrease in persistence of neuroparalysis (Dolly and
O’Connell, 2012). In these days, a faster and more efﬁcient
BoNT-based neurotherapeutics becomes a possibility
considering the advances in protein engineering.
BoNT/A has been under clinical trials for treatment of
migraine and other chronic pain for many years. Therefore,
the translation of the encouraging results from preclinical
studies in animal pain models to clinical treatments of
more various types of chronic pain in human sufferers can
be a signiﬁcant step. However, more in depth studies are
necessary to reach to a point where it can be clinically
applicable. None of the previous studies have established
the exact mechanism responsible for analgesic effects of
BoNT/A; which could provide the essential foundation of
developing future therapeutic strategies. Besides, there is a
lack of precise applicable doses and injecting sites to refer
to. Therefore, more studies are required to determine the
best and accurate method of using BoNT/A is the goal of
many ongoing efforts. With all this said, there is still a great
potential for BoNT/A in the treatment of chronic pain.
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